180 related articles for article (PubMed ID: 23624802)
21. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
22. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Eigentler TK; Gutzmer R; Hauschild A; Heinzerling L; Schadendorf D; Nashan D; Hölzle E; Kiecker F; Becker J; Sunderkötter C; Moll I; Richtig E; Pönitzsch I; Pehamberger H; Kaufmann R; Pföhler C; Vogt T; Berking C; Praxmarer M; Garbe C;
Ann Oncol; 2016 Aug; 27(8):1625-32. PubMed ID: 27287206
[TBL] [Abstract][Full Text] [Related]
24. Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.
Tarhini AA; Lin Y; Zahoor H; Shuai Y; Butterfield LH; Ringquist S; Gogas H; Sander C; Lee S; Agarwala SS; Kirwood JM
PLoS One; 2015; 10(7):e0132745. PubMed ID: 26192408
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Sondak VK; Flaherty LE
Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
[No Abstract] [Full Text] [Related]
26. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
27. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
[No Abstract] [Full Text] [Related]
28. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
Kirkwood JM; Manola J; Ibrahim J; Sondak V; Ernstoff MS; Rao U;
Clin Cancer Res; 2004 Mar; 10(5):1670-7. PubMed ID: 15014018
[TBL] [Abstract][Full Text] [Related]
29. ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).
Go RS; Lee SJ; Shin D; Callister SM; Jobe DA; Conry RM; Tarhini AA; Kirkwood JM
Clin Cancer Res; 2013 Dec; 19(23):6597-604. PubMed ID: 24122792
[TBL] [Abstract][Full Text] [Related]
30. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
31. The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.
Akman T; Oztop I; Baskin Y; Akbarpour M; Unal OU; Oflazoglu U; Ellidokuz H; Lebe B
Med Oncol; 2015 Jan; 32(1):440. PubMed ID: 25502087
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.
Gogas H; Kefala G; Bafaloukos D; Frangia K; Polyzos A; Pectasides D; Tsoutsos D; Panagiotou P; Ioannovich J; Loukopoulos D
Br J Cancer; 2002 Jul; 87(2):181-6. PubMed ID: 12107840
[TBL] [Abstract][Full Text] [Related]
33. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
34. [Current aspects of adjuvant therapy of malignant melanoma].
Kähler KC; Egberts F; Hauschild A
Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
[TBL] [Abstract][Full Text] [Related]
35. Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Mocellin S; Lens MB; Pasquali S; Pilati P; Chiarion Sileni V
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008955. PubMed ID: 23775773
[TBL] [Abstract][Full Text] [Related]
36. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
Gogas H; Kirkwood JM; Falk CS; Dafni U; Sondak VK; Tsoutsos D; Stratigos A; Markopoulos C; Pectasides D; Spyropoulou-Vlachou M
Cancer; 2010 Sep; 116(18):4326-33. PubMed ID: 20549830
[TBL] [Abstract][Full Text] [Related]
37. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
[TBL] [Abstract][Full Text] [Related]
38. Melanoma and IFN alpha: potential adjuvant therapy.
Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
40. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]